Detailed Quote
Questions on this company?
Become a Member
Company Profile
{tplLang.businessdescription | toLang tLang}
{ profileData.description }
{tplLang.details | toLang tLang}
{tplLang.ceo | toLang tLang}
{profileData.profile.details.ceo}
{tplLang.employees | toLang tLang}
{profileData.profile.details.employees | numeraljs '0,0'}
{tplLang.issuetype | toLang tLang}
{profileData.profile.details.issuetype | asIssueType}
{tplLang.industryclassifications | toLang tLang}
{tplLang.sector | toLang tLang}
{profileData.profile.classification.sector}
{tplLang.industry | toLang tLang}
{profileData.profile.classification.industry}
{tplLang.toolname| toLang tLang}
There is no {tplLang.toolname| toLang tLang} currently available for
{data.symbolstring}.
Interactive Chart
Key Ratios
Earnings
Analyst Recommendations
5i Recent Questions
Q: Hi,
HEPION Parma (HEPA-US: not in your database) had a 1/20 reverse stock split this week. Taking this into account, the stock is still nearly down 50% in 2 days. Liver/ NASH disease is a good research target. Any news I did not see?
Have a great week-end. Thanks
HEPION Parma (HEPA-US: not in your database) had a 1/20 reverse stock split this week. Taking this into account, the stock is still nearly down 50% in 2 days. Liver/ NASH disease is a good research target. Any news I did not see?
Have a great week-end. Thanks
Insiders
Share Information
News and Media